Visceral pain
nausea or vomiting, bloating, visceral pain, fatigue, abdominal pain, pain, dizziness, hypoxemia, headache, abdominal bloating
ADVERSE EVENTS, ADVERSE EVENT
The incidence of visceral pain at 10 min after recovery was significantly lower with butorphanol (31.5% Comparison of efficacy and safety outcomes (median and interquartile range or frequency and percentage)Incidence of visceral pain recovery at 10 (The incidence of visceral pain at 20 and 30 min after recovery showed a similar change (Fig. Perioperative monitoring parameters (MAP, SpO2 and RR).The MAP, SpOChanges in MAP, HR, SpO2, and RR. MAP, HR: Normal distribution, mean, and SD. SpO2, RR: Nonnormal distribution, median, and upper/lower limit. T0, at admission; T1, before anesthesia; T2, 5 min after propofol administration; T3, at the end of the operation; T4, 5 min in the PACU; T5, 10 min after recovery; T6, 30 min after recovery. Only after the administration (T2, t = -2.716, Adverse events.Only one patient in the butorphanol group developed fatigue during the operation and recovery room. After 24 h of recovery in the butorphanol group, the number of people with nausea or vomiting, abdominal bloating, dizziness, or headache was 2, 7, and 5, respectively. In Group II, only seven people had abdominal pain and bloating. No cases of hypoxemia or body movements were reported. There were no significant differences between the two groups in adverse events (